Systematic review on oncologic outcomes on adjuvant endovesical treatment for non-muscle invasive bladder cancer in patients with solid organ transplant.
Matthieu SimonetAna Dominguez GutierrezAngelo TerritoThomas PrudhommeRicardo CampiIulia AndrasMichael BaboudjianVital HeviaRomain Boissiernull nullPublished in: World journal of urology (2022)
In solid organ transplanted patients under immunosuppressive treatment, both endovesical chemotherapy and BCG are safe, but the level of evidence concerning efficacy in comparison with the general population is low. According to these results, adjuvant treatment should be proposed for NMIC in transplanted patients as in the general population.
Keyphrases
- systematic review
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- prostate cancer
- muscle invasive bladder cancer
- radiation therapy
- rectal cancer
- minimally invasive
- weight loss
- radical prostatectomy
- smoking cessation